Athanor Capital’s BridgeBio Pharma BBIO Stock Holding History

Athanor Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,131	Closed	-$293K	–	473
2021 Q1	$316K	Sell	5,131 -8,809	-63%	-$576K	0.01%	580
2020 Q4	$991K	Sell	13,940 -5,594	-29%	-$270K	0.02%	324
2020 Q3	$733K	Sell	19,534 -9,424	-33%	-$297K	0.03%	278
2020 Q2	$944K	Buy	+28,958	New	+$882K	0.05%	200
2020 Q1	–	Sell	-35,283	Closed	-$1.24M	–	183
2019 Q4	$1.24M	Sell	35,283 -1,665	-5%	-$46.2K	0.06%	140
2019 Q3	$793K	Buy	+36,948	New	+$1.02M	0.05%	132

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Athanor Capital's BBIO Position: Q2 2021 in Review

Athanor Capital sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 5,131 shares — an estimated $293K sold.

Athanor Capital first reported a position in BBIO in Q3 2019 and held it in 6 quarters. The position peaked at $1.24M in Q4 2019. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Athanor Capital reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
Athanor Capital sold 5,131 BridgeBio Pharma shares in Q2 2021, an estimated $293K.
Athanor Capital first reported a position in BridgeBio Pharma in Q3 2019 and held it in 6 quarters.
Athanor Capital's BridgeBio Pharma position peaked at $1.24M in Q4 2019.
200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.